Quest Diagnostics CEO Davis sells $10.5 million in stock

Quest Diagnostics (NYSE:DGX) CEO and President Davis J. E. sold a total of $10.5 million in company stock on November 25, 2025. The sales involved 55,293 shares of common stock, with prices ranging from $191.5888 to $192.9717.

On the same day, Davis also exercised options to acquire 55,093 shares of Quest Diagnostics common stock at a price of $95.795, for a total value of $5277633. These transactions were executed under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, Davis directly owns 120,480 shares of Quest Diagnostics.

In other recent news, Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on January 28, 2026, to shareholders of record as of January 13, 2026. The company also reported strong third-quarter results, surpassing both Truist Securities’ and consensus expectations for earnings and revenue. Following these results, Truist Securities increased its price target for Quest Diagnostics from $195 to $205, while maintaining a Hold rating. Similarly, Leerink Partners raised its price target from $203 to $210, citing a favorable environment in the laboratory services sector.

Meanwhile, Hims & Hers Health is expanding its services by launching lab testing in collaboration with Quest Diagnostics. This initiative allows customers to access testing at over 1,000 Quest Diagnostics locations across the country. Users will receive results and can consult with providers on the Hims & Hers platform for personalized health plans. Additionally, Engine Capital, a significant shareholder of UniFirst Corporation, has publicly urged the company to consider a sale. This call came after unsuccessful private discussions with company trustees regarding governance practices.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.